A regulatory T cell signature distinguishes the immune landscape of COVID-19 patients from those with other respiratory infections
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
Unique circulating regulatory T cell phenotypes distinguish hospitalized patients with SARS-CoV-2.
Article activity feed
-
-
SciScore for 10.1101/2021.03.25.21254376: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Antibodies Sentences Resources Single-stained controls were prepared with every experiment using antibody capture beads diluted in FACS buffer (BD Biosciences anti-mouse, #552843, anti-rat, #552844, and Miltenyi anti-REA, #130-1040693). anti-mousesuggested: (BD Biosciences Cat# 552843, RRID:AB_10051478)anti-rat,suggested: (BD Biosciences Cat# 552844, RRID:AB_10055784)anti-REAsuggested: NoneSoftware and Algorithms Sentences Resources All samples were acquired using a FACSymphony A5 (BD Biosciences), equipped with 30 … SciScore for 10.1101/2021.03.25.21254376: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Antibodies Sentences Resources Single-stained controls were prepared with every experiment using antibody capture beads diluted in FACS buffer (BD Biosciences anti-mouse, #552843, anti-rat, #552844, and Miltenyi anti-REA, #130-1040693). anti-mousesuggested: (BD Biosciences Cat# 552843, RRID:AB_10051478)anti-rat,suggested: (BD Biosciences Cat# 552844, RRID:AB_10055784)anti-REAsuggested: NoneSoftware and Algorithms Sentences Resources All samples were acquired using a FACSymphony A5 (BD Biosciences), equipped with 30 detectors and 355nm (65mW), 405nm (200mW), 488nm (200mW), 532nm (200mW) and 628nm (200mW) lasers and FACSDiva acquisition software (BD Biosciences). BD Biosciencessuggested: (BD Biosciences, RRID:SCR_013311)FACSDivasuggested: (BD FACSDiva Software, RRID:SCR_001456)After acquisition, data was exported in FCS 3.1 format and analyzed using FlowJo (version 10.7.x, BD Biosciences). FlowJosuggested: (FlowJo, RRID:SCR_008520)Statistical Analysis: After testing the normal distribution of our data using the D’Agostino & Person test, statistical analyses were performed using either an ordinary one-way ANOVA (parametric test) or Kruskal Wallis test (nonparametric test) using the GraphPad Software. GraphPadsuggested: (GraphPad Prism, RRID:SCR_002798)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:Our study has some limitations, first of which is our exclusive focus on peripheral blood immune responses rather than tissue-specific responses. In addition, our cohort includes patient sample collection from variable times post-symptom onset, from zero to 47 days. This variability could clearly impact the types of immune phenotypes detected, as could variability in viral loads and durability of viral shedding, for which we are lacking data from the majority of patients due to scarcity of testing in the early days of the pandemic. Finally, while we were powered to uncover unique aspects of the circulating Treg phenotypes of patients with SARS-CoV-2 compared to Flu or RSV, our relatively small N (Table 1) may have precluded identification of other distinguishing immune phenotypes. In sum, our study based on high dimensional flow cytometry data combined with several analysis methods reveals a largely similar immune landscape of patients hospitalized with respiratory virus infections, including SARS-CoV-2. This is further supported by our analysis of 71 soluble cytokines and chemokines in the blood of patients with SARS-CoV-2, Flu, or RSV. The recent identification of novel SARS-CoV-2 variants that may increase transmission and alter vaccine efficacy70 underscores the need for continued development of treatment strategies specifically for severe COVID-19 disease course. Thus, we speculate that the overlapping immune landscapes in SARS-CoV-2, Flu, and RSV infections could be lev...
Results from TrialIdentifier: We found the following clinical trial numbers in your paper:
Identifier Status Title NCT04435522 Completed Maraviroc in Patients With Moderate and Severe COVID-19 NCT04500418 Recruiting Charité Trial of Cenicriviroc (CVC) Treatment for COVID-19 P… Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-
